Ocular Therapeutix (OCUL) Net Income towards Common Stockholders (2013 - 2026)

Ocular Therapeutix's Net Income towards Common Stockholders history runs 14 years deep, the most recent figure standing at -$90.1 million for Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 42.79% year-over-year to -$90.1 million in Q1 2026; TTM through Mar 2026 was -$292.7 million, a 49.03% decrease from a year earlier, with the FY2025 full-year figure at -$544.1 million, down 44.42% from the prior year.
• Net Income towards Common Stockholders declined to -$90.1 million in Q1 2026 per OCUL's latest filing, from -$67.5 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at -$16.3 million in Q4 2022 and bottomed at -$90.1 million in Q1 2026.
• The 5-year median for Net Income towards Common Stockholders is -$40.7 million (2024), against an average of -$41.4 million.
• Across the five-year window, Net Income towards Common Stockholders grew 17.29% in 2022 and plunged 103.33% in 2024, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$16.3 million in 2022, then sank by 65.91% to -$27.1 million in 2023, then tumbled by 81.09% to -$49.0 million in 2024, then slumped by 37.66% to -$67.5 million in 2025, then tumbled by 33.5% to -$90.1 million in 2026.
• Per Business Quant, the three latest OCUL Net Income towards Common Stockholders figures stand at -$90.1 million (Q1 2026), -$67.5 million (Q4 2025), and -$68.0 million (Q3 2025).